Rhabdomyolysis in association with simvastatin and amiodarone

被引:60
作者
Roten, L
Schoenenberger, RA
Krähenbühl, S
Schlienger, RG
机构
[1] Univ Basel Hosp, Div Clin Pharmacol & Toxicol, Dept Internal Med, Reg Pharmacovigilance Ctr, CH-4031 Basel, Switzerland
[2] Burgerspital, Dept Internal Med, Solothurn, Switzerland
[3] Univ Basel Hosp, Drug Informat Unit, CH-4031 Basel, Switzerland
[4] Univ Basel, Inst Clin Pharm, Dept Pharm, Basel, Switzerland
关键词
amiodarone; myopathy; rhabdomyolysis; simvastatin;
D O I
10.1345/aph.1D498
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To report a case of severe myopathy associated with concomitant simvastatin and amiodarone therapy. CASE SUMMARY: A 63-year-old white man with underlying insulin-dependent diabetes, recent coronary artery bypass surgery, and postoperative hemiplegia was treated with aspirin, metoprolol, furosemide, nitroglycerin, and simvastatin. Due to recurrent atrial fibrillation, oral anticoagulation with phenprocoumon and antiarrhythmic treatment with amiodarone were initiated. Four weeks after starting sirrivastatin 40 mg/day and 2 weeks after initiating amiodarone 1 g/day for 10 days, then 200 mg/day, he developed diffuse muscle pain with generalized muscular weakness. Laboratory investigations revealed a significant increase of creatine kinase (CK) peaking at 40 392 U/L. Due to a suspected drug interaction of sirrivastatin with amiodarone, both drugs were stopped. CK normalized over the following 8 days, and the patient made an uneventful recovery. An objective causality assessment revealed that the myopathy was probably related to simvastatin. DISCUSSION: Myopathy is a rare but potentially severe adverse reaction associated with statins. Besides high statin doses, concomitant use of fibrates, defined comorbidities, and concurrent use of inhibitors of cytochrome P450 are important additional risk factors. This is especially relevant if statins predominantly metabolized by CYP3A4 are combined with inhibitors of this isoenzyme. Amiodarone is a potent inhibitor of several different CYP isoenzymes, including CYP3A4. CONCLUSIONS: Avoiding the concomitant use of drugs with the potential to inhibit CYP-dependent metabolism (eg, amiodarone) or elimination of statins may decrease the risk of statin-associated myopathy. Alternatively, if drug therapy with a potent CYP inhibitor is inevitable, choosing a statin without relevant CYP metabolism (eg, pravastatin) should be considered.
引用
收藏
页码:978 / 981
页数:4
相关论文
共 25 条
[1]   Risk for myopathy with statin therapy in high-risk patients [J].
Ballantyne, CM ;
Corsini, A ;
Davidson, MH ;
Holdaas, H ;
Jacobson, TA ;
Leitersdorf, E ;
März, W ;
Reckless, JPD ;
Stein, EA .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :553-564
[2]  
BONNET C, 1995, REV RHUM, V62, P468
[3]   ACUTE NECROTIZING MYOPATHY ASSOCIATED WITH AMIODARONE THERAPY [J].
CLOUSTON, PD ;
DONNELLY, PE .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1989, 19 (05) :483-485
[4]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[5]   HYPOTHYROID MYOPATHY - A CASE WITH DRAMATIC INCREASE OF CREATINE-PHOSPHOKINASE, MYOGLOBINEMIA AND TRANSIENT RENAL-FAILURE [J].
GEPNER, P ;
BOTTO, H ;
PIETTE, AM ;
GRAVELEAU, P ;
CHAPMAN, A .
REVUE DE MEDECINE INTERNE, 1990, 11 (02) :165-167
[6]   Statin-associated myopathy [J].
Hamilton-Craig, I .
MEDICAL JOURNAL OF AUSTRALIA, 2001, 175 (09) :486-+
[7]   Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) [J].
Igel, M ;
Sudhop, T ;
vonBergmann, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (05) :357-364
[8]  
MALLARET M, 1993, PRESSE MED, V22, P272
[9]   Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class - Are they clinically relevant? [J].
Martin, J ;
Krum, H .
DRUG SAFETY, 2003, 26 (01) :13-21
[10]   The effects of amiodarone on the thyroid [J].
Martino, E ;
Bartalena, L ;
Bogazzi, F ;
Braverman, LE .
ENDOCRINE REVIEWS, 2001, 22 (02) :240-254